Sch 22591 (5-episisomicin), gentamicin, sisomicin, and tobramycin were compared for their ability to protect mice from lethal intraperitoneal challenge with 12 Pseudomonas strains, all susceptible to each of the aminoglycosides (minimal inhibitory concentrations and minimal bactericidal concentrations were -6.2 ,ug/ml). Median 50% protective doses were 5.8, 6.4, 7.7, and 17.8 mg/kg for Sch 22591, tobramycin, sisomicin, and gentamicin, respectively. Those for Sch 22591 were significantly lower than gentamicin in five protection tests and significantly lower than both gentamicin and tobramycin in one test. Microbial analysis of the therapeutic effect indicated that protection from lethality by each of the four aminoglycosides was associated with either a complete eradication or a reduction in the number of challenge bacteria in both the heart blood and peritoneum. In rare instances, challenge isolates exhibiting decreased susceptibility to one or more of the aminoglycosides were recovered from animals. However, this in vivo selection of resistance did not appear related to either the aminoglycoside used in therapy or the outcome of therapy, and resistant isolates were recovered as frequently from untreated animals as from those receiving one of the four aminoglycosides.
Sch 22591 (5-episisomicin) is a new semisynthetic aminoglycoside structurally similar to sisomicin. In vitro, Sch 22591 has been shown to possess greater activity than gentamicin, sisomicin, tobramycim, amikacin, netilmicin, or kanamycin against a variety of gram-positive and gram-negative organisms (5, 7) . In vivo, Sch 22591 also appears to be more active than other aminoglycosides in the treatment of mice infected with Pseudomonas aeruginosa (7) . In view of the greater activity of Sch 22591 over other aminoglycosides, studies were performed to evaluate this compound more extensively in vivo. These studies were designed to compare Sch 22591, sisomicin, gentamicin, and tobramycin for their ability to (i) protect mice lethally infected with a variety of Pseudomonas species, (ii) eradicate or reduce the number of the challenge bacteria in the heart blood and peritoneum of infected mice, and (iii) select aminoglycosideresistant bacteria in vivo. Microbial analy8is of the therapeutic effect. Cultures of heart blood and peritoneum were performed on blood agar plates immediately after death of the mice or, for survivors, after cervical dislocation 48 h after infection. Animals cultured included two dead animals from the untreated control group and at least two dead and two surviving animals in (i) the dose group nearest the PD50 or (ii) the highest dose group in tests in which protection failed to occur. Cultures were performed as follows. The surface of the peritoneal cavity was swabbed with a sterile cotton-tip swab, which was then used to inoculate a sheep blood agar plate. Heart blood was removed with a tuberculin syringe, and several drops of blood were placed on a blood agar plate. Both of these blood agar plates were then serially streaked with a loop through the four quadrants of the plate for dilution and isolation of the colonies (2) . The quantity of the challenge strain recovered on peritoneal cultures was estimated by using a scale from 1+ to 4+ based on the presence of colonies in the various quadrants inoculated, in which 1+, 2+, 3+, and 4+ indicate, respectively, growth only in the first quadrant (one to 100 colonies), growth in the first and second quadrants (102 to 103 colonies), growth in the first, second, and third quadrants (103 to 104 colonies), and solid growth in all four quadrants (over 10' colonies). The identity of challenge isolates recovered on these cultures was confirmed by biochemical tests (Oxifern, Roche Diagnostics). For the heart blood another blood agar plate was inoculated whenever possible with 0.01 ml of blood (calibrated loop) to estimate the number of bacteria per ml. These isolates (10 to 20 colonies) and the original challenge strain were also tested for their susceptibility to the four drugs used in the protection tests by dilution assay in Mueller-Hinton broth with an inoculum of 10' colony-forming units (CFU) per ml.
MATERIALS AND METHODS
Peritoneal cultures were used for susceptibility testing only when blood cultures were negative. Results from cultures of heart blood were analyzed to determine the occurrence and degree of bacteremia among survivors and among animals dying of the infection within 48 h. All but one animal dying within 48 h of challenge had bacteremia (Table 2) . Among the survivors, significantly fewer mice had bacteremia, regardless of which aminoglycoside was used in therapy. There was no significant difference in the percentage of survivors with bacteremia between the four aminoglycosides used in therapy.
RESULTS
Results of bacterial counts on heart blood were analyzed to determine the effect of aminoglycoside therapy on the degree of bacteremia. The small number of surviving animals with detectable bacteremia had fewer organisms per ml of blood than animals dying of the infection within 48 h ( Table 2) . Among animals dying of the infection, 98% had -104 CFU/ml of blood, whereas 98% of survivors had _103 CFU/ml of blood. These results indicate that protection from lethality by each of the four aminoglycosides was associated with reduction or eradication of the bacteremia.
As with heart blood cultures, fewer peritoneal cultures from surviving animals were positive for the challenge strain than were cultures from dead animals ( Table 3 The quantity of the challenge strain recovered on peritoneal cultures was estimated, and the results for dead and surviving animals were compared (Table 3) . As with heart blood cultures, a smaller quantity of the challenge strain was recovered from surviving animals than from those dying of the infection. Peritoneal cultures from 88 of 96 survivors (92%) contained 1+ or less of the challenge strain, whereas cultures from 195 of 197 dead animals (99%) contained 3+ or more. Thus, protection from lethality by each of the four aminoglycosides was also associated with reduction or eradication of the challenge strain from the peritoneum.
Susceptibility of challenge isolates recovered from mice. After completion of each protection test, challenge isolates recovered from (i) two control mice and (ii) two dead and two surviving animals from the dose group nearest the PD50 were tested for their susceptibility to each of the four aminoglycosides. Results were compared to the antibiotic susceptibility determined for the challenge isolates before animal passage. An isolate was considered to be more resistant to an aminoglycoside if minimal inhibitory concentration and/or minimal bactericidal concentration values were increased fourfold or more above values obtained for the strain before animal passage.
Of 181 animal isolates tested, only 4 were more resistant to the aminoglycoside used in therapy. Seventeen isolates were more resistant to an aminoglycoside not used in therapy. However, these changes did not appear to have influenced the outcome of the protection tests, since similar changes occurred with isolates recovered from three of the untreated control animals. In addition, all changes in susceptibility were small (none greater than eightfold). Although gentamicin failed to protect 50% of the mice injected with P. putrefaciens 2, no resistant strains were recovered from gentamicin-treated animals. Also, all drugs failed to protect 50% of animals injected with P. aeruginosa 138, but no uniform selection of resistance was noted.
DISCUSSION
In treatment of the experimental infections examined in this study, Sch 22591 was generally the most effective, sisomicin and tobramycin were intermediate, and gentamicin was the least effective. Similar relationships between the three latter antibiotics have been described by previous investigators (1, 4, 6, 8) . Heart blood and peritoneal cultures obtained from infected animals demonstrated that the peritoneal infection model was almost uniformly followed by bacteremia. Analysis of postchallenge cultures indicated a clear association between animal survival and reduction or clearance of the bacteria from both heart blood and peritoneum. The antibiotics appeared similar in their overall ability to clear the challenge organisms from both heart blood and peritoneum. However, the animal survival associated with this clearance was generally effected by a lower dose (i.e., lower PD50) of Sch 22591 compared to the other aminoglycosides examined.
